应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09939 开拓药业-B
耶稣受难节休市 03-28 16:08:03
0.860
+0.020
+2.38%
最高
0.900
最低
0.830
成交量
121.05万
今开
0.860
昨收
0.840
日振幅
8.33%
总市值
3.85亿
流通市值
3.85亿
总股本
4.47亿
成交额
105.66万
换手率
0.27%
流通股本
4.47亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
兄弟科技(002562.SZ):兄弟医药的碘帕醇原料药产品获得印度注册证书
港股那点事 · 03-28 22:07
兄弟科技(002562.SZ):兄弟医药的碘帕醇原料药产品获得印度注册证书
开拓药业-B(09939)发布2023年度业绩,净亏损10.6亿元,同比扩大11.2%
智通财经网 · 03-28 21:18
开拓药业-B(09939)发布2023年度业绩,净亏损10.6亿元,同比扩大11.2%
3月28日亚泰集团涨停分析:振兴东北,疫苗,医药概念热股
证券之星 · 03-28 15:50
3月28日亚泰集团涨停分析:振兴东北,疫苗,医药概念热股
亚盛医药-B(06855)下跌20.0%,报17.56元/股
金融界 · 03-28 15:25
亚盛医药-B(06855)下跌20.0%,报17.56元/股
亚盛医药-B(06855)股价大幅下跌17.175%,现价港币$18.18
阿斯达克财经 · 03-28 14:20
亚盛医药-B(06855)股价大幅下跌17.175%,现价港币$18.18
亚盛医药-B盘中异动 早盘股价大跌9.24%报19.921港元
自选股智能写手 · 03-28 09:37
亚盛医药-B盘中异动 早盘股价大跌9.24%报19.921港元
医药一季度业绩转好,券商看好布局窗口期
每日经济新闻 · 03-28 09:28
医药一季度业绩转好,券商看好布局窗口期
知名医药巨头宣布,重磅新药获批!1瓶定价10万,影响多大?
每日经济新闻 · 03-28 09:22
知名医药巨头宣布,重磅新药获批!1瓶定价10万,影响多大?
专注构建全球化研产销创新闭环,亚盛医药-B(06855)稳步向Biopharma转型发展
智通财经网 · 03-28 07:50
专注构建全球化研产销创新闭环,亚盛医药-B(06855)稳步向Biopharma转型发展
亚盛医药(6855.HK)公布2023年业绩:自我造血能力持续提升 产品管线潜力丰富
格隆汇资讯 · 03-27 22:44
亚盛医药(6855.HK)公布2023年业绩:自我造血能力持续提升 产品管线潜力丰富
亚盛医药-B(06855)公布2023年业绩 全球临床开发迎收获期
智通财经 · 03-27 22:24
亚盛医药-B(06855)公布2023年业绩 全球临床开发迎收获期
万春医药下跌2.77%,报3.51美元/股
金融界 · 03-27 22:19
万春医药下跌2.77%,报3.51美元/股
3月27日江苏吴中跌5.29%,申万菱信医药先锋股票A基金重仓该股
证券之星 · 03-27 16:48
3月27日江苏吴中跌5.29%,申万菱信医药先锋股票A基金重仓该股
开拓药业-B盘中异动 临近收盘大幅跳水5.62%报0.840港元
自选股智能写手 · 03-27 15:49
开拓药业-B盘中异动 临近收盘大幅跳水5.62%报0.840港元
3月27日圣达生物涨停分析:维生素,化学原料药,医药概念热股
证券之星 · 03-27 15:46
3月27日圣达生物涨停分析:维生素,化学原料药,医药概念热股
3月27日博晖创新涨停分析:血制品,猴痘概念,医药概念热股
证券之星 · 03-27 15:45
3月27日博晖创新涨停分析:血制品,猴痘概念,医药概念热股
3月27日康惠制药涨停分析:长寿药NMN,中药,医药概念热股
证券之星 · 03-27 15:44
3月27日康惠制药涨停分析:长寿药NMN,中药,医药概念热股
3月27日大理药业涨停分析:新冠药物,中药,医药概念热股
证券之星 · 03-27 15:44
3月27日大理药业涨停分析:新冠药物,中药,医药概念热股
成都跃居医药即时零售“第二城”,美团买药多举措力促生态共建
第一财经 · 03-27 14:22
成都跃居医药即时零售“第二城”,美团买药多举措力促生态共建
浙商证券:当前医药破局重要新业态 CSO板块未来或支撑业内相关标的成长性等
智通财经 · 03-27 11:24
浙商证券:当前医药破局重要新业态 CSO板块未来或支撑业内相关标的成长性等
公司概况
公司名称:
开拓药业-B
所属市场:
SEHK
上市日期:
--
主营业务:
开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。
发行价格:
--
{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":0.86,"timestamp":1711613283021,"preClose":0.84,"halted":0,"volume":1210500,"delay":0,"floatShares":447499600,"shares":447499600,"eps":-2.7320895,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":0.02,"latestTime":"03-28 16:08:03","open":0.86,"high":0.9,"low":0.83,"amount":1056635,"amplitude":0.083333,"askPrice":0.88,"askSize":70500,"bidPrice":0.86,"bidSize":19000,"shortable":0,"etf":0,"ttmEps":-1.7125632387813239,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1590076800000,"adjPreClose":0.84,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":1.277438,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939/wiki","defaultTab":"wiki","newsList":[{"id":"2422197208","title":"兄弟科技(002562.SZ):兄弟医药的碘帕醇原料药产品获得印度注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2422197208","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2422197208?lang=zh_cn&edition=full","pubTime":"2024-03-28 22:07","pubTimestamp":1711634856,"startTime":"0","endTime":"0","summary":"格隆汇3月28日丨兄弟科技(002562.SZ)公布,公司全资子公司江西兄弟医药有限公司(简称“兄弟医药”)于近日收到印度中央药品标准管理局(Central Drugs Standard ControlOrganisation)卫生和家庭福利部(Ministry of Health & Family Welfare)关于原料药产品的注册证书。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-28/doc-inapwvcn5364872.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-28/doc-inapwvcn5364872.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422199254","title":"开拓药业-B(09939)发布2023年度业绩,净亏损10.6亿元,同比扩大11.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422199254","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422199254?lang=zh_cn&edition=full","pubTime":"2024-03-28 21:18","pubTimestamp":1711631929,"startTime":"0","endTime":"0","summary":"开拓药业-B(09939)发布截至2023年12月31日止年度业绩,集团并无批准进...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_32.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_32.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1095325.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422137153","title":"3月28日亚泰集团涨停分析:振兴东北,疫苗,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422137153","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2422137153?lang=zh_cn&edition=full","pubTime":"2024-03-28 15:50","pubTimestamp":1711612239,"startTime":"0","endTime":"0","summary":"证券之星消息,亚泰集团涨停收盘,收盘价1.63元。近5日资金流向一览见下表:该股为振兴东北,疫苗,医药概念热股,当日振兴东北概念上涨1.69%,疫苗概念上涨1.23%,医药概念上涨0.98%。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024032800025267.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422134208","title":"亚盛医药-B(06855)下跌20.0%,报17.56元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422134208","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422134208?lang=zh_cn&edition=full","pubTime":"2024-03-28 15:25","pubTimestamp":1711610726,"startTime":"0","endTime":"0","summary":"3月28日,亚盛医药-B盘中下跌20.0%,截至15:25,报17.56元/股,成交1.95亿元。亚盛医药集团是一家专注于肿瘤、乙肝及与衰老相关疾病治疗领域的创新药物开发的生物医药企业,拥有自主构建的蛋白-蛋白相互作用靶向药物设计平台,并已建立9个已进入临床开发阶段的1类小分子新药产品管线。截至2023年年报,亚盛医药-B营业总收入2.22亿元、净利润-9.26亿元。3月27日,2023财年年报归属股东应占溢利-9.256亿人民币,同比下降4.84%,基本每股收益-3.28人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/28152540034595.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422913599","title":"亚盛医药-B(06855)股价大幅下跌17.175%,现价港币$18.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2422913599","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422913599?lang=zh_cn&edition=full","pubTime":"2024-03-28 14:20","pubTimestamp":1711606800,"startTime":"0","endTime":"0","summary":"[下跌股]亚盛医药-B(06855) 股价在下午02:20比前收市价大幅下跌17.175%,现股价为港币$18.18。至目前为止,今日最高价为$20.7,而最低价为$18.18。总成交量为716.12万股,总成交金额为港币$1.417亿。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2403282374/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2422903077","title":"亚盛医药-B盘中异动 早盘股价大跌9.24%报19.921港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422903077","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422903077?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:37","pubTimestamp":1711589835,"startTime":"0","endTime":"0","summary":"2024年03月28日早盘09时37分,亚盛医药-B股票出现异动,股价急速下挫9.24%。截至发稿,该股报19.921港元/股,成交量120.14万股,换手率0.41%,振幅3.19%。资金方面,该股资金流入726.748万港元,流出854.865万港元。亚盛医药-B股票所在的生物技术行业中,整体跌幅为0.12%。亚盛医药-B公司简介:亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328093715791d6324&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328093715791d6324&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422903964","title":"医药一季度业绩转好,券商看好布局窗口期","url":"https://stock-news.laohu8.com/highlight/detail?id=2422903964","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2422903964?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:28","pubTimestamp":1711589280,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 据国信证券预测,A股医药生物行业51家公司中增长超10%企业或较多,业绩具有一定韧性。政策端对于创新药和创新器械的支持导向明显,创新药预计将从药学、临床价值和循证证据三个方面来区分是否为高质量创新,并给予创新性强的产品在定价、挂网等环节的政策支持。 当前医药行业处于低估值、低交易关注度阶段,或正在进入中长期拐点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hyyj/2024-03-28/doc-inapvtsa2585697.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2024-03-28/doc-inapvtsa2585697.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422798908","title":"知名医药巨头宣布,重磅新药获批!1瓶定价10万,影响多大?","url":"https://stock-news.laohu8.com/highlight/detail?id=2422798908","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2422798908?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:22","pubTimestamp":1711588965,"startTime":"0","endTime":"0","summary":"医药巨头突传重大利好。美东时间周二,美国医药巨头默沙东(MRK,股价:131.75美元;总市值:3337亿美元)宣布,其用于治疗一种可致命肺病的新药获得美国食品药品监督管理局(FDA)批准。图片来源:默沙东官网截图截至美股收盘,默沙东股价大涨约5%创历史新高,最新总市值升至3337亿美元(约合人民币24000亿元)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403283027241795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283027241795.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422796759","title":"专注构建全球化研产销创新闭环,亚盛医药-B(06855)稳步向Biopharma转型发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2422796759","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422796759?lang=zh_cn&edition=full","pubTime":"2024-03-28 07:50","pubTimestamp":1711583429,"startTime":"0","endTime":"0","summary":"依托全球化研发、海外注册以及市场商业化等多方面形成的体系化优势,亚盛医药在不断兑现自身造血潜能的同时也在推动创新研发踏上新台阶,进一步完善自身向Biopharma跃迁发展的“正循环”。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240328/20240328075054_41911.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240328/20240328075054_41911.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094322.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422291176","title":"亚盛医药(6855.HK)公布2023年业绩:自我造血能力持续提升 产品管线潜力丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2422291176","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422291176?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:44","pubTimestamp":1711550680,"startTime":"0","endTime":"0","summary":"亚盛医药公布2023年业绩:实现收入人民币2.22亿元,收入主要来自产品销售和合作里程碑收入。亚盛医药上市产品耐立克是中国目前首个且唯一获批上市的第三代BCR-ABL抑制剂。2023年1月,耐立克作为“国产创新药标杆”纳入2022年国家医保药品目录,极大提升患者用药可及性,并加速推动该产品的商业化放量。新适应症的获批大幅扩大了患者适用人群,为耐药患者带来新的治疗选择,2024年有望进一步提升耐立克的商业化表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722444487bcaca1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722444487bcaca1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422913292","title":"亚盛医药-B(06855)公布2023年业绩 全球临床开发迎收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2422913292","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422913292?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:24","pubTimestamp":1711549479,"startTime":"0","endTime":"0","summary":"智通财经APP讯,3月27日,亚盛医药-B 公布2023年全年业绩:报告期内亚盛医药实现总收入人民币2.22亿元。随着亚盛医药核心产品耐立克被纳入国家医保目录并获新适应症上市批准,以及通过加快进院准入、病人累积、用药持续时间延长,预期更多的患者将获益于耐立克的治疗方案,带动2024年销售增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093987.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422915167","title":"万春医药下跌2.77%,报3.51美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422915167","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422915167?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:19","pubTimestamp":1711549185,"startTime":"0","endTime":"0","summary":"3月27日,万春医药(BYSI)盘中下跌2.77%,截至22:19,报3.51美元/股,成交6.34万美元。财务数据显示,截至2023年06月30日,万春医药收入总额87.5万美元,同比增长29.44%;归母净利润-1272.0万美元,同比增长31.2%。大事提醒:4月16日,万春医药将披露2023财年年报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/27221940024053.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422954738","title":"3月27日江苏吴中跌5.29%,申万菱信医药先锋股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422954738","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2422954738?lang=zh_cn&edition=full","pubTime":"2024-03-27 16:48","pubTimestamp":1711529320,"startTime":"0","endTime":"0","summary":"证券之星消息,3月27日江苏吴中跌5.29%创60日新高,收盘报10.75元,换手率15.87%,成交量112.64万手,成交额13.05亿元。根据2023基金年报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为申万菱信医药先锋股票A。申万菱信医药先锋股票A目前规模为2.95亿元,最新净值0.6309,较上一交易日下跌0.24%,近一年下跌25.63%。申万菱信医药先锋股票A的前十大重仓股如下:以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024032700031590.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422295313","title":"开拓药业-B盘中异动 临近收盘大幅跳水5.62%报0.840港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422295313","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422295313?lang=zh_cn&edition=full","pubTime":"2024-03-27 15:49","pubTimestamp":1711525741,"startTime":"0","endTime":"0","summary":"2024年03月27日临近收盘15时49分,开拓药业-B股票出现波动,股价急速下跌5.62%。截至发稿,该股报0.840港元/股,成交量194.4万股,换手率0.43%,振幅6.74%。资金方面,该股资金流入13.456万港元,流出140.936万港元。开拓药业-B股票所在的药品行业中,整体跌幅为0.08%。其相关个股中,天大药业、翰森制药、远大医药涨幅较大,振幅较大的相关个股有泰凌医药、三爱健康集团、华控康泰,振幅分别为14.29%、11.63%、9.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327154901861e1a55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327154901861e1a55&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422953780","title":"3月27日圣达生物涨停分析:维生素,化学原料药,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422953780","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2422953780?lang=zh_cn&edition=full","pubTime":"2024-03-27 15:46","pubTimestamp":1711525573,"startTime":"0","endTime":"0","summary":"证券之星消息,圣达生物涨停收盘,收盘价15.51元。该股于9点25分涨停,未打开涨停,截止收盘封单资金为8219.9万元,占其流通市值3.1%。近5日资金流向一览见下表:该股为维生素,化学原料药,医药概念热股,当日维生素概念上涨1.67%。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024032700026161.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422955344","title":"3月27日博晖创新涨停分析:血制品,猴痘概念,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422955344","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2422955344?lang=zh_cn&edition=full","pubTime":"2024-03-27 15:45","pubTimestamp":1711525544,"startTime":"0","endTime":"0","summary":"证券之星消息,博晖创新涨停收盘,收盘价5.63元。该股于9点33分涨停,未打开涨停,截止收盘封单资金为6844.34万元,占其流通市值1.53%。近5日资金流向一览见下表:该股为血制品,猴痘概念,医药概念热股。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024032700026134.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422953010","title":"3月27日康惠制药涨停分析:长寿药NMN,中药,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422953010","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2422953010?lang=zh_cn&edition=full","pubTime":"2024-03-27 15:44","pubTimestamp":1711525495,"startTime":"0","endTime":"0","summary":"证券之星消息,康惠制药涨停收盘,收盘价15.97元。该股于10点19分涨停,1次打开涨停,截止收盘封单资金为1091.07万元,占其流通市值0.68%。近5日资金流向一览见下表:该股为长寿药NMN,中药,医药概念热股,当日长寿药NMN概念上涨5.08%。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024032700026070.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422953735","title":"3月27日大理药业涨停分析:新冠药物,中药,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422953735","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2422953735?lang=zh_cn&edition=full","pubTime":"2024-03-27 15:44","pubTimestamp":1711525441,"startTime":"0","endTime":"0","summary":"证券之星消息,大理药业涨停收盘,收盘价12.8元。该股于14点20分涨停,未打开涨停,截止收盘封单资金为1027.14万元,占其流通市值0.37%。近5日资金流向一览见下表:该股为新冠药物,中药,医药概念热股。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024032700026001.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422939452","title":"成都跃居医药即时零售“第二城”,美团买药多举措力促生态共建","url":"https://stock-news.laohu8.com/highlight/detail?id=2422939452","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2422939452?lang=zh_cn&edition=full","pubTime":"2024-03-27 14:22","pubTimestamp":1711520532,"startTime":"0","endTime":"0","summary":"为助力医药商家即时零售业务更好发展,3月26日美团买药在成都举办了第一届商家生态大会,邀请泉源堂大药房、健之佳、叮当快药、海王星辰健康药房、高济医疗、全亿健康药房等连锁药店到场,共同探索成都医药即时零售市场的高质量发展路径,共建和谐积极的行业生态。“2024年是医药即时零售市场的生态建设元年,美团买药未来会协同更多成都本地行业伙伴,探索数字化发展的新通路,激发行业创新潜力。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327142223791d2633&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327142223791d2633&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422986023","title":"浙商证券:当前医药破局重要新业态 CSO板块未来或支撑业内相关标的成长性等","url":"https://stock-news.laohu8.com/highlight/detail?id=2422986023","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422986023?lang=zh_cn&edition=full","pubTime":"2024-03-27 11:24","pubTimestamp":1711509889,"startTime":"0","endTime":"0","summary":"现阶段,基于对当前宏观环境及医改持续深化方向的判断,CSO板块是当前医药破局重要的新业态,其经营趋势变化或将支撑业态内标的成长性及盈利能力超市场预期。浙商证券主要观点如下:CSO:产业趋势下的新业态浙商证券认为,医药逐渐进入供给侧改革新阶段。CSO是创新产业链不断细化的必然产物。浙商证券认为,盈利能力与产品IP归属、产品发展阶段及CSO对产品的赋能相关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093162.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.1042},{"period":"1month","weight":-0.3813},{"period":"3month","weight":-0.4724},{"period":"6month","weight":-0.6861},{"period":"1year","weight":-0.8822},{"period":"ytd","weight":-0.4724}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.058646},{"month":2,"riseRate":0.75,"avgChangeRate":0.213088},{"month":3,"riseRate":0.25,"avgChangeRate":0.058957},{"month":4,"riseRate":0.666667,"avgChangeRate":0.700374},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.091618},{"month":6,"riseRate":0.25,"avgChangeRate":-0.077338},{"month":7,"riseRate":0.75,"avgChangeRate":0.030119},{"month":8,"riseRate":0.25,"avgChangeRate":-0.047081},{"month":9,"riseRate":0,"avgChangeRate":-0.284122},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084422},{"month":11,"riseRate":0.75,"avgChangeRate":0.089012},{"month":12,"riseRate":0.25,"avgChangeRate":-0.241375}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}